Triple

T6216918
Position Surface form Disambiguated ID Type / Status
Subject Committee for Medicinal Products for Human Use E139009 entity
Predicate worksWith P398 FINISHED
Object Committee for Advanced Therapies E23508 NE FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Committee for Advanced Therapies | Statement: [Committee for Medicinal Products for Human Use, worksWith, Committee for Advanced Therapies]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Committee for Advanced Therapies
Context triple: [Committee for Medicinal Products for Human Use, worksWith, Committee for Advanced Therapies]
  • A. Committee for Advanced Therapies chosen
    The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
  • B. Committee on Development, Regeneration and Stem Cell Biology
    The Committee on Development, Regeneration and Stem Cell Biology is an academic program at the University of Chicago focused on research and graduate training in developmental biology, tissue regeneration, and stem cell science.
  • C. Office of Tissues and Advanced Therapies
    The Office of Tissues and Advanced Therapies is a U.S. FDA office responsible for regulating cellular and gene therapies, tissue-based products, and other advanced biologic treatments.
  • D. Committee for Orphan Medicinal Products
    The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
  • E. Center for Cellular and Molecular Therapeutics
    The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c008aecb0c81909984b48f733ce8ae completed March 22, 2026, 3:20 p.m.
NER Named-entity recognition batch_69c062a1eb3881908c7f735cf9c429ce completed March 22, 2026, 9:44 p.m.
NED1 Entity disambiguation (via context triple) batch_69c20db4e0ac8190ba7bca1f9d8ac6df completed March 24, 2026, 4:06 a.m.
Created at: March 22, 2026, 4:21 p.m.